ライフサイエンスコーパス: Fms-like tyrosine kinase 3

1 l cell line-derived neurotrophic factor, and FMS-like tyrosine kinase-3.

2 A 46-year-old white woman with a history of Fms-like tyrosine kinase 3 acute myeloid leukemia presen

3 verexpression have been identified including FMS-like tyrosine kinase-3 and nucleophosmin, which will

4 DC), the majority of which were derived from fms-like tyrosine kinase 3-dependent pre-DC, and CD11b(+

5 and primary patient specimens independent of Fms-like tyrosine kinase 3 expression and stromal-mediat

6 tion activating gene 1(+) lymphomyeloid, and Fms-like tyrosine kinase 3(+) fetal monocyte lineages.

7 ophage colony stimulating factor I receptor (Fms)-like tyrosine kinase 3 (Flt-3) ligand supported fur

8 Increases in fms-like tyrosine kinase-3 (FLT-3) ligand, reflecting FL

9 in or point mutation in the kinase domain of FMS-like tyrosine kinase-3 (FLT-3) mediates ligand-indep

10 'FMS'-like tyrosine kinase 3 (FLT3) mutations in acute my

11 Mutations of Fms-like tyrosine kinase 3 (FLT3) are among the most fre

12 Activating mutations in FMS-like tyrosine kinase 3 (FLT3) are common in acute my

13 Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approxi

14 Constitutive activation of FMS-like tyrosine kinase 3 (FLT3) by internal tandem dup

15 Internal tandem duplication (ITD) of fms-like tyrosine kinase 3 (FLT3) in acute myeloid leuke

16 goal of this study was to define the role of FMS-like tyrosine kinase 3 (FLT3) in the heart.

17 nd the ensuing expansion of T(reg) cells are Fms-like tyrosine kinase 3 (Flt3) independent, occur in

18 Fms-like tyrosine kinase 3 (FLT3) inhibition has elicite

19 seen to emerge as resistant mutations after FMS-like tyrosine kinase 3 (FLT3) inhibitor therapy.

20 teosome inhibitors, antiangiogenesis agents, Fms-like tyrosine kinase 3 (FLT3) inhibitors, and apopto

21 Oncogenic addiction to the Fms-like tyrosine kinase 3 (FLT3) is a hallmark of acute

22 FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine

23 Fms-like tyrosine kinase 3 (FLT3) is a receptor tyrosine

24 Fms-like tyrosine kinase 3 (Flt3) is a type III receptor

25 FMS-like tyrosine kinase 3 (FLT3) is almost universally

26 FMS-like tyrosine kinase 3 (FLT3) is expressed in human

27 FMS-like tyrosine kinase 3 (FLT3) is mutated in approxim

28 Signal transduction of FMS-like tyrosine kinase 3 (FLT3) is regulated by protei

29 e myeloid leukemia (AML) and determined that FMS-like tyrosine kinase 3 (FLT3) is transactivated by S

30 xclusively from pre-DCs under the control of fms-like tyrosine kinase 3 (Flt3) ligand, inhibitor of D

31 Fms-like tyrosine kinase 3 (FLT3) mutations are associat

32 Ever since the recognition that FMS-like tyrosine kinase 3 (FLT3) mutations exert a prof

33 Activating FMS-like tyrosine kinase 3 (FLT3) mutations have been id

34 Constitutively activating mutations of FMS-like tyrosine kinase 3 (FLT3) occur in approximately

35 Mutations that activate the fms-like tyrosine kinase 3 (FLT3) receptor are among the

36 rnal tandem duplication (ITD) mutants of the Fms-like tyrosine kinase 3 (Flt3) receptor in leukemogen

37 Internal tandem duplications (ITDs) of the FMS-like tyrosine kinase 3 (FLT3) receptor tyrosine kina

38 The fms-like tyrosine kinase 3 (FLT3) receptor tyrosine kina

39 mia (AML) harbor activating mutations in the FMS-like tyrosine kinase 3 (FLT3) receptor tyrosine kina

40 l-3-kinase (PI3K)/protein kinase B (AKT) and Fms-like tyrosine kinase 3 (FLT3) signaling are aberrant

41 on of HoxA9 and Meis1a and with mutations in FMS-like tyrosine kinase 3 (FLT3) to drive acute leukemi

42 Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain

43 FMS-like tyrosine kinase 3 (FLT3), a class III receptor

44 aled that normal villus epithelium expresses Fms-like tyrosine kinase 3 (Flt3), a known regulator of

45 ation and discovered that ADP transactivates Fms-like tyrosine kinase 3 (Flt3), a receptor tyrosine k

46 cation (ITD) in the juxtamembrane portion of Fms-like tyrosine kinase 3 (FLT3), a type III receptor t

47 The ligand for the receptor tyrosine kinase fms-like tyrosine kinase 3 (flt3), also referred to as f

48 r of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived grow

49 iated by HSC-specific genes such as CD34 and Fms-like tyrosine kinase 3 (FLT3), respectively.

50 Small molecule inhibitors that target fms-like tyrosine kinase 3 (FLT3)-activating mutations h

51 Multiple FMS-like tyrosine kinase 3 (FLT3)-inhibitors have been s

52 Signaling pathways regulated by mutant Fms-like tyrosine kinase 3 (FLT3)-internal tandem duplic

53 Rhesus macaques were injected with Fms-like tyrosine kinase 3 (Flt3)-ligand (FL) to expand

54 FMS-like tyrosine kinase 3 (FLT3)-mutant acute myeloid l

55 tion was identified in the gene encoding the Fms-like tyrosine kinase 3 (Flt3).

56 yrosine kinase domain (TKD) mutations of the fms-like tyrosine kinase-3 (FLT3) gene in acute myeloid

57 We examined 6 different FMS-like tyrosine kinase-3 (FLT3) inhibitors (lestaurtin

58 Fms-like tyrosine kinase-3 (FLT3) inhibitors have been u

59 Fms-like tyrosine kinase-3 (Flt3) ligand (FL) and Interl

60 viously demonstrated that pretreatments with fms-like tyrosine kinase-3 (Flt3) ligand (Flt3L), a dend

61 In a randomized trial of therapy for FMS-like tyrosine kinase-3 (FLT3) mutant acute myeloid l

62 al tandem duplication (ITD) mutations of the FMS-like tyrosine kinase-3 (FLT3) receptor found in acut

63 Activating mutations of the FMS-like tyrosine kinase-3 (FLT3) receptor occur in appr

64 andem duplication (ITD) mutations within the FMS-like tyrosine kinase-3 (FLT3) render the receptor co

65 FMS-like tyrosine kinase-3 (FLT3) tyrosine kinase inhibi

66 r of clinical trials testing the efficacy of FMS-like tyrosine kinase-3 (FLT3) tyrosine kinase inhibi

67 Mutant Fms-Like Tyrosine kinase-3 (FLT3), which is expressed in

68 The clinical benefit of adding FMS-like tyrosine kinase-3 (FLT3)-directed small molecul

69 FMS-like tyrosine kinase-3 (FLT3)-internal tandem duplic

70 rbor a constitutively activating mutation in FMS-like tyrosine kinase-3 (FLT3).

71 cluding 14 (93%) of 15 patients with mutated FMS-like tyrosine kinase-3 (FLT3; the 15th patient had c

72 e myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3).

73 ecreased in Mysm1(-/-) mice and defective in Fms-like tyrosine kinase-3(Flt3) ligand-induced, but not

74 expansion, cooperated with mutations in the FMS-like tyrosine kinase 3 gene (Flt3(ITD)) and the nucl

75 An internal tandem duplication in the fms-like tyrosine kinase 3 gene (FLT3/ITD) is associated

76 is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhib

77 In Fms-like tyrosine kinase 3 internal tandem duplication (

78 In Fms-like tyrosine kinase 3 internal tandem duplication (

79 In FMS-like tyrosine kinase 3-internal tandem duplication (

80 FMS-like tyrosine kinase 3-internal tandem duplication (

81 enic tyrosine kinases, including BCR-ABL and FMS-like tyrosine kinase 3-internal tandem duplication (

82 f a juxtamembrane mutation in the FLT3 gene (FMS-like tyrosine kinase 3-internal tandem duplication [

83 Distinct expression patterns for FMS-like tyrosine kinase 3-internal tandem duplication w

84 treated with the hematopoietic growth factor fms-like tyrosine kinase 3 ligand (FL), which dramatical

85 C precursors that can be expanded in vivo by Fms-like tyrosine kinase 3 ligand (FL).

86 Fms-like tyrosine kinase 3 ligand (Flt3L) administration

87 observation that Langerin-CD11b- migDCs are Fms-like tyrosine kinase 3 ligand (Flt3L) dependent and

88 Here, we observe subcutaneous immunity is Fms-like tyrosine kinase 3 ligand (Flt3L) dependent.

89 In contrast, injection of FMS-like tyrosine kinase 3 ligand (Flt3L) DNA, which exp

90 und that immunization of wild-type mice with FMS-like tyrosine kinase 3 ligand (Flt3L) DNA, which inc

91 Fms-like tyrosine kinase 3 ligand (Flt3L) expands dendri

92 Fms-like tyrosine kinase 3 ligand (Flt3L) is a hematopoi

93 ested this hypothesis by using DC-deficient, fms-like tyrosine kinase 3 ligand (Flt3L) knockout (KO)

94 Daily treatment of mice with fms-like tyrosine kinase 3 ligand (Flt3L) leads to a sig

95 Fms-like tyrosine kinase 3 ligand (Flt3L) mobilizes stem

96 Conversely, endogenous DC expansion using FMS-like tyrosine kinase 3 ligand (Flt3L) protected mice

97 In this study we demonstrate that Fms-like tyrosine kinase 3 ligand (Flt3L) recruits plasm

98 Fms-like tyrosine kinase 3 ligand (Flt3L) reverses the f

99 d deficiency (DCML deficiency) with elevated Fms-like tyrosine kinase 3 ligand (Flt3L) was observed i

100 ge inflammatory protein-1alpha (MIP-1alpha), fms-like tyrosine kinase 3 ligand (Flt3L), and the DNA v

101 Multiple subsets of FMS-like tyrosine kinase 3 ligand (FLT3L)-dependent dend

102 ministration of the potent DC growth factor, fms-like tyrosine kinase 3 ligand (Flt3L).

103 ne liver pDCs, we expanded them in vivo with fms-like tyrosine kinase 3 ligand (Flt3L).

104 Mice lacking fms-like tyrosine kinase 3 ligand (Flt3L-/-) as the resu

105 rotein 3alpha (hCCL20/hMIP-3alpha), or human fms-like tyrosine kinase 3 ligand (hFlt3-L), factors pre

106 IP-1alpha) and the DC-specific growth factor fms-like tyrosine kinase 3 ligand with the DNA vaccine r

107 SCs in normal mice in response to SCF, IL-7, fms-like tyrosine kinase 3 ligand, and IL-15.

108 nes, including caveolin-1, semaphorin E, and FMS-like tyrosine kinase 3 ligand, have putative roles i

109 ter their stimulation with stem cell factor, Fms-like tyrosine kinase 3 ligand, interleukin-3, interl

110 DC progenitors and accumulate in response to Fms-like tyrosine kinase 3 ligand, yet appear divergent

111 lls were defective in generating pDCs in the fms-like tyrosine kinase 3 ligand-based culture system a

112 DC differentiation depends on IRF-4, whereas Fms-like tyrosine kinase 3 ligand-mediated differentiati

113 freshly isolated, immunobead-purified (>90%) fms-like tyrosine kinase 3 ligand-mobilized C57BL/10 (B1

114 DNA that encoded the secreted form of human fms-like tyrosine kinase 3 ligand.

115 Fms-like tyrosine kinase-3 ligand (Flt3L) is a hemopoiet

116 mon DC progenitor with conventional DCs, and Fms-like tyrosine kinase-3 ligand is essential for their

117 rsely, DC expansion induced either by Flt3L (fms-like tyrosine kinase-3 ligand) or adoptive transfer

118 kin-7, interleukin-15, stem cell factor, and fms-like tyrosine kinase-3 ligand).

119 endothelial cells were identified: endoglin, Fms-like tyrosine kinase-3 ligand, EGF-like repeats and

120 Recently, Flt3 (Fms-like tyrosine kinase 3)-ligand has been identified a

121 ion with the receptor tyrosine kinases FLT3 (Fms-like tyrosine kinase 3) or KIT-induced ligand indepe

122 ations of the receptor tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) play an important role in le

123 The protein kinase fms-like tyrosine kinase 3 receptor (Flt3) has an import

124 ns leading to constitutive activation of the FMS-like tyrosine kinase 3 receptor (FLT3) occur in blas

125 The ligand for the FMS-like tyrosine kinase 3 receptor (Flt3L) is necessary

126 ndritic cells (cDCs) requires the ligand for FMS-like tyrosine kinase 3 receptor (flt3L), but little

127 Internal tandem duplication of the Fms-like tyrosine kinase-3 receptor (FLT3) internal tand